SNN SMITH & NEPHEW PLC IFRS Annual reports only
Orthopedic, Prosthetic & Surgical Appliances & Supplies · NYSE · SEC CIK 845982 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY2025*2025-12-31 | FY2024*2024-12-31 | FY2023*2023-12-31 | FY2022*2022-12-31 | FY2021*2021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $6.16B | $5.81B | $5.55B | $5.21B | $5.21B |
| Cost of revenue | $1.97B | $1.76B | $1.73B | $1.54B | $1.54B |
| Gross profit | $4.19B | $4.05B | $3.82B | $3.67B | $3.67B |
| R&D expense | $296.00M | $289.00M | $339.00M | $345.00M | $356.00M |
| SG&A expense | $3.10B | $3.10B | $3.06B | $2.88B | $2.72B |
| Operating income | $794.00M | $657.00M | $425.00M | $450.00M | $593.00M |
| Interest expense | $140.00M | $145.00M | $132.00M | $80.00M | $80.00M |
| Pretax income | $779.00M | $498.00M | $290.00M | $235.00M | $586.00M |
| Income tax | $154.00M | $86.00M | $27.00M | $12.00M | $62.00M |
| Net income | $625.00M | $412.00M | $263.00M | $223.00M | $524.00M |
| EPS (basic) | 0.72 | 0.47 | 0.30 | 0.26 | 0.60 |
| EPS (diluted) | 0.72 | 0.47 | 0.30 | 0.26 | 0.60 |
| Weighted avg. shares (diluted) | 873.00M | 876.00M | 873.00M | 873.00M | 878.00M |
| Banking | |||||
| Net interest income | -$112.00M | -$121.00M | -$98.00M | -$66.00M | -$74.00M |
| Balance sheet | |||||
| Cash & equivalents | $557.00M | $619.00M | $302.00M | $350.00M | $1.28B |
| Receivables | $1.41B | $1.38B | $1.30B | $1.26B | $1.18B |
| Inventory | $2.12B | $2.39B | $2.40B | $2.21B | $1.84B |
| Current assets | $4.10B | $4.42B | $4.03B | $3.86B | $4.42B |
| PP&E, netmay include right-of-use assets (IFRS) | $1.64B | $1.42B | $1.47B | $1.46B | $1.51B |
| Goodwill | $3.11B | $3.03B | $2.99B | $3.03B | $2.99B |
| Intangibles | $882.00M | $1.03B | $1.11B | $1.24B | $1.40B |
| Total assets | $10.46B | $10.35B | $9.99B | $9.97B | $10.92B |
| Current liabilities | $1.59B | $1.53B | $2.27B | $1.72B | $2.13B |
| Short-term debt | $83.00M | $2.00M | $710.00M | $111.00M | $435.00M |
| Total liabilities | $5.17B | $5.09B | $4.77B | $4.71B | $5.35B |
| Shareholders' equity | $5.29B | $5.26B | $5.22B | $5.26B | $5.57B |
| Cash flow statement | |||||
| Operating cash flow | $1.28B | $987.00M | $608.00M | $468.00M | $877.00M |
| Investing cash flow | -$406.00M | -$569.00M | -$448.00M | -$472.00M | -$691.00M |
| Financing cash flow | -$955.00M | -$86.00M | -$200.00M | -$926.00M | -$645.00M |
| Stock-based compensation | $43.00M | $40.00M | $39.00M | $40.00M | $41.00M |
| Dividends paid | $330.00M | $327.00M | $327.00M | $327.00M | $329.00M |
| Share buybacks | $502.00M | — | — | $158.00M | — |
Free plan shows the latest 5 periods; Pro shows all 11 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.